5、消化系统肿瘤消化系统肿瘤 (11).pdf

Journal of Clinical Oncology List of Issues Volume 38,Issue 15_suppl Meeting Abstract|2020 ASCO Annual Meeting IGASTROINTESTINAL CANCERGASTROESOPHAGEAL,PANCREATIC,ANDHEPATOBILIARYPhase II study assessing tolerability,efficacy,and biomarkers for durvalumab(D)tremelimumab(T)and gemcitabine/cisplatinRights&PermissionsOPTIONS&TOOLSExport CitationTrack CitationAdd To FavoritesADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article Tools(GemCis)in chemo-nave advanced biliarytract cancer(aBTC).Do-Youn Oh,Kyung-Hun Lee,Dae-Won Lee,Tae Yong Kim,Ju-Hee Bang,Ah-Rong Nam,.Show MoreAbstract Disclosures4520Background:In aBTC,GemCis is the standard ofcare as 1-line treatment.Immunotherapies haveshown early promising efficacy in some BTCpatients(pts).We assessed D(anti-PD-L1)T(anti-CTLA-4)and GemCis in 1L BTC pts,includingan extensive biomarker analysis(NCT03046862).Methods:Pts were first enrolled in the biomarkercohort(BMC)to receive 1 cycle of Gem 1000mg/m +Cis 25 mg/m on D1&D8,followed byGemCis+D 1120 mg and T 75 mg,Q3W untildisease progression(PD).Subsequent pts wereCOMPANION ARTICLESNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2020.38.15_suppl.4520Journal of Clinical Oncology 38,no.15_suppl(May 20,2020)4520-4520.Published online May 25,2020.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certified or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at the Beach inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractst22Standard cisplatin/infusional 5-fluorouracil(PF)vs docetaxel(T)plusPF(TPF)as neoadjuvantchemotherapy for nonresectablelocally advanced squamous cellcarcinoma of the head andneck(LA-SCCHN):a phase III trial of theEORTC Head and Neck Cancer Group(EORTC#24971)J.B.Vermorken et al.,J Clin Oncol,2004Kinetics of Liquid Biopsies inPredicting Response toImmunotherapyPashtoon M.Kasi et al.,ASCO DailyNews,2020allocated to GemCis+D(3 combo cohort 3C)orGemCis+D+T(4 combo cohort 4C)until PD.In allcohorts,tumor biopsies were obtained pre-treatment,after 1 cycle,and at PD.Blood samplesfor ctDNA were obtained every cycle.Results:121pts were enrolled.Median follow-up durationswere 28.5 months(m;95%CI,26.5-30.5),11.3 m(95%CI,9.1-13.5),and 11.9m(95%CI,8.4-15.4)inthe BMC,3C,and 4C arms,respectively.Efficacydata are shown(Table).The most commonadverse events(AEs,any grade)were neutropenia(54.5%),nausea(59.5%),and pruritus(55.44%).The most common grade 3/4 AEs wereneutropenia(50.4%),anemia(35.5%),andthrombocytopenia(16.5%).In the BMC cohort,frequent mutations were found in DNA damagerepair,cell cycle regulation,and genomeinstability genes(eg,ATM,BRCA2,POLE,MSH2,CDKN2A).Distinct somatic variants were detectedin responders vs non-responders.Baseline tissueTMB did not correlate with PFS or OS.Reductionsin ctDNA variant allele frequency(VAF)were moreprominent among responders during early D+TADVERTISEMENTEpirubicin(E),cisplatin(C)andcapecitabine(X)in first-linechemotherapy for patients withadvanced gastric cancerE.K.Cho et al.,J Clin Oncol,2004Dynamic Changes of CirculatingTumor DNA Predict Clinical Outcomein Patients With Advanced NonSmall-Cell Lung Cancer Treated WithImmune Checkpoint InhibitorsSabrina Weber et al.,JCO PO,2021TOMOX compared to FOLFOX4 asfirst-line treatment in patients(pts)with advanced colorectal cancer(ACRC):Preliminary results of amulticenter randomized phase II trialC.Grvalos et al.,J Clin Oncol,2004Camrelizumab plus gemcitabine andoxaliplatin(GEMOX)in patients withadvanced biliary tract cancer:asingle-arm,open-label,phase II trialXiaofeng Chen et al.,Jitc,2020Efficacy and biomarker analysis ofnivolumab plus gemcitabine andcisplatin in patients withunresectable or metastatic biliarytract cancers:results from a phase IIstudyKaichao Feng et al.,Jitc,2020Novel biomarkers predict benefitwith immunotherapy in metastaticbreast cancerMedicalXpress,2020Assessment of Blood TumorMutational Burden as a Potentialcycles.ctDNA VAF on C3,D1 was significantlycorrelated with ORR(P 0.015).Pretreatment PD-L1 expression was not associated with efficacy,butPD-L1 expression after 1 GemCis cycle trendedwith improved PFS.Conclusions:These are thefirst clinical data of DT plus chemotherapy inchemo-nave aBTC pts.The addition ofimmunotherapy to chemotherapy was tolerableand showed very promising efficacy.Biomarkeranalyses show early signs of markers associatedwith response.The combination of GemCis+D isbeing investigated in the Phase 3 TOPAZ-1 trial(NCT03875235).Clinical trial information:NCT03046862.BMC(n=30)3C(n=45)4C(n=46)ORR(95%CI),%50.0(32.1-67.9)73.4(60.5-86.3)73.3(60.4-86.2)DCR(95%CI),%96.7(90.3-100)100(100-100)97.8(93.5-100)mDOR(95%CI),m11.0(3.9-11.8)9.8(8.1-11.4)9.1(4.5-15.0)mPFS(95%CI),m13.0(10.1-15.9)11.0(7.0-15.0)11.9(10.1-13.7)stBiomarker for Immunotherapy inPatients With NonSmall Cell LungCancer With Use of a Next-Generation Sequencing Cancer GenePanelZhijie Wang et al.,JAMA Oncology,2019Prospect of liquid biopsy applicationfor precise medication of PD-1/PD-L1inhibitorYuehua Wang et al.,Chinese ScienceBulletin,2018Powered byBMC(n=30)3C(n=45)4C(n=46)mOS(95%CI),m15.0(10.7-19.3)18.1(11.3-24.9)20.7(13.8-27.6)2020 American Society of Clinical OncologyResearch Sponsor:AstraZenecaQUICK LINKSContentNewest Articles Archive Meeting AbstractsJournal InformationAbout Editorial Roster Contact Us PermissionsResourcesAuthors Reviewers Subscribers Institutions AdvertisersSubmit Your ManuscriptSubscribe to this JournalASCO FAMILY OF SITESJournalsJournal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision OncologyPublicationsASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post EducationASCO eLearning ASCO Meetings Cancer.NetOther SitesASCO.org ASCO Author Services ASCO Career Center CancerLinQ Conquer Cancer Foundation TAPUR Study American Society of Clinical Oncology Terms of Use|Privacy Policy|Cookies2318 Mill Road,Suite 800,Alexandria,VA 22314 2021 American Society of Clinical Oncology